Long-term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3-year results from two randomized phase III trials (CIMPASI-1 and CIMPASI-2)
K B Gordon, R B Warren, A B Gottlieb, A Blauvelt, D Thaçi, C Leonardi, Y Poulin, M Boehnlein, F Brock, C Ecoffet, K Reich, K B Gordon, R B Warren, A B Gottlieb, A Blauvelt, D Thaçi, C Leonardi, Y Poulin, M Boehnlein, F Brock, C Ecoffet, K Reich
Abstract
Background: Certolizumab pegol (CZP) is an Fc-free, PEGylated anti-tumour necrosis factor biologic.
Objectives: To report the 3-year efficacy of CZP in plaque psoriasis, pooled from the CIMPASI-1 (NCT02326298) and CIMPASI-2 (NCT02326272) phase III trials.
Methods: Adults with moderate-to-severe psoriasis for ≥ 6 months were randomized 2 : 2 : 1 to CZP 200 mg, CZP 400 mg or placebo, every 2 weeks (Q2W) for up to 48 weeks. Patients entering the open-label period (weeks 48-144) from double-blinded CZP initially received CZP 200 mg Q2W. Patients not achieving ≥ 50% improvement in Psoriasis Area and Severity Index (PASI 50) at week 16 entered an open-label CZP 400 mg Q2W escape arm (weeks 16-144). Dose adjustments based on PASI response were permitted during open-label treatment. Outcomes included PASI 75, PASI 90 and Physician's Global Assessment (PGA) 0/1 responder rates, based on a logistic regression model (missing data imputed using Markov Chain Monte Carlo methodology).
Results: In total, 186 patients were randomized to CZP 200 mg Q2W and 175 to CZP 400 mg Q2W. At week 48, PASI 75/90 was achieved by 72·7%/51·3% of patients randomized to CZP 200 mg and 84·4%/62·7% randomized to CZP 400 mg. Patients entering the open-label period at week 48, from blinded treatment, received CZP 200 mg Q2W. At week 144, PASI 75/90 was achieved by 70·6%/48·7% patients randomized to CZP 200 mg and 72·9%/42·7% randomized to CZP 400 mg. At week 16, 72 placebo-randomized patients entered the CZP 400 mg Q2W escape arm; 75.7%/58.5% achieved PASI 75/90 at week 144.
Conclusions: Both CZP 200 mg and 400 mg Q2W demonstrated sustained, durable efficacy, with numerically higher responses for some outcomes with 400 mg Q2W.
© 2020 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.
Figures
References
- Menter A, Strober BE, Kaplan DH et al. Joint AAD‐NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol 2019; 80:1029–72.
- National Institute for Health and Care Excellence . NICE pathways: psoriasis overview. Available at: (last accessed 8 July 2020).
- Menter A, Korman NJ, Elmets CA et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol 2009; 60:643–59.
- Menter A, Korman NJ, Elmets CA et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol 2009; 61:451–85.
- Elmets CA, Lim HW, Stoff B et al. Joint American Academy of Dermatology‐National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy. J Am Acad Dermatol 2019; 81:775–804.
- Ighani A, Yu AM, Sandhu VK et al. Satisfaction and awareness of systemic psoriasis treatments: a national survey comparing biologic and nonbiologic users. J Cutan Med Surg 2019; 23:148–56.
- Gisondi P, Del Giglio M, Girolomoni G. Treatment approaches to moderate to severe psoriasis. Int J Mol Sci 2017; 18:2427.
- Levin EC, Gupta R, Brown G et al. Biologic fatigue in psoriasis. J Dermatolog Treat 2014; 25:78–82.
- Strober BE, van der Walt JM, Armstrong AW et al. Clinical goals and barriers to effective psoriasis care. Dermatol Ther 2019; 9:5–18.
- Electronic Medicines Compendium . Cimzia. Available at: (last accessed 8 July 2020).
- Food and Drug Administration . Cimzia prescribing information. Available at: (last accessed 8 July 2020).
- Mariette X, Förger F, Abraham B et al. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. Ann Rheum Dis 2018; 77:228–33.
- Baker T, Kevorkian L, Nesbitt A. Investigation into the binding affinity of certolizumab pegol to FcRn and functional consequences for FcRn‐mediated transcytosis: comparison to infliximab, adalimumab and etanercept. Ann Rheum Dis 2013; 72:A426.
- Weir N, Athwal D, Brown D et al. A new generation of high‐affinity humanized PEGylated Fab′ fragment anti‐tumor necrosis factor‐α monoclonal antibodies. Therapy 2006; 3:535–45.
- Blauvelt A, Reich K, Lebwohl M et al. Certolizumab pegol for the treatment of patients with moderate‐to‐severe chronic plaque psoriasis: pooled analysis of week 16 data from three randomized controlled trials. J Eur Acad Dermatol 2019; 33:546–52.
- Gottlieb AB, Blauvelt A, Thaçi D et al. Certolizumab pegol for the treatment of chronic plaque psoriasis: results through 48 weeks from 2 phase 3, multicenter, randomized, double‐blinded, placebo‐controlled studies (CIMPASI‐1 and CIMPASI‐2). J Am Acad Dermatol 2018; 79:302–14.
- Lebwohl M, Blauvelt A, Paul C et al. Certolizumab pegol for the treatment of chronic plaque psoriasis: results through 48 weeks of a phase 3, multicenter, randomized, double‐blind, etanercept‐and placebo‐controlled study (CIMPACT). J Am Acad Dermatol 2018; 79:266–76.
- Blauvelt A, Paul C, van de Kerkhof P et al. Long‐term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo‐controlled studies. Br J Dermatol 2021; 184:640–51.
- Keystone E, Landewé R, van Vollenhoven R et al. Long‐term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5‐year results from the RAPID 1 trial and open‐label extension. Ann Rheum Dis 2014; 73:2094–100.
- Sandborn W, Lee S, Randall C et al. Long‐term safety and efficacy of certolizumab pegol in the treatment of Crohn’s disease: 7‐year results from the PRECiSE 3 study. Aliment Pharm Ther 2014; 40:903–16.
- van der Heijde D, Dougados M, Landewé R et al. Sustained efficacy, safety and patient‐reported outcomes of certolizumab pegol in axial spondyloarthritis: 4‐year outcomes from RAPID‐axSpA. Rheumatology 2017; 56:1498–509.
- van der Heijde D, Deodhar A, FitzGerald O et al. 4‐year results from the RAPID‐PsA phase 3 randomised placebo‐controlled trial of certolizumab pegol in psoriatic arthritis. RMD Open 2018; 4:e000582.
- Gordon K, Papp K, Poulin Y et al. Long‐term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open‐label extension study for patients from REVEAL. J Am Acad Dermatol 2012; 66:241–51.
- Bissonnette R, Luger T, Thaci D et al. Secukinumab sustains good efficacy and favourable safety in moderate‐to‐severe psoriasis after up to 3 years of treatment: results from a double‐blind extension study. Br J Dermatol 2017; 177:1033–42.
Source: PubMed